行情

LIFE

LIFE

aTyr制药
NASDAQ

实时行情|Nasdaq Last Sale

3.910
+0.270
+7.42%
盘后: 3.920 +0.01 +0.26% 18:35 08/13 EDT
开盘
3.650
昨收
3.640
最高
3.990
最低
3.500
成交量
15.80万
成交额
--
52周最高
7.62
52周最低
2.130
市值
3,656.83万
市盈率(TTM)
-0.8597
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测LIFE价格均价为11.50,最高价位15.00,最低价为8.00。

EPS

LIFE 新闻

更多
aTyr Pharma Q2 EPS $(0.69) Beats $(0.73) Estimate, Sales $189.00K Up From $94.00K YoY
aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.73) by 5.48 percent. This is a 61.67 percent increase over losses of $(1.80) per share from the
Benzinga · 6小时前
The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 13小时前
aTyr Pharma Highlights Partner, Kyorin Pharma, Will Proceed To Phase 1 Trial Of ATYR1923 In Japan
Benzinga · 2天前
aTyr Pharma Highlights Partner, Kyorin Pharma, Will Proceed To Phase 1 Trial Of ATYR1923 In Japan
Benzinga · 2天前
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial Results
Management to host conference call and webcast on August 13th at 5:00 pm EDT / 2:00 pm PDTSAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines
GlobeNewswire · 08/06 12:01
Atyr Pharma (LIFE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/05 16:30
Edited Transcript of LIFE earnings conference call or presentation 12-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 06/22 21:52
aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II
SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster and audio presentation at the 20
GlobeNewswire · 06/22 12:00

所属板块

生物技术和医学研究
+0.99%
制药与医学研究
-0.06%

热门股票

代码
价格
涨跌幅

LIFE 简况

aTyr Pharma, Inc.是一家临床阶段的生物治疗公司。该公司利用其Physiocrine生物科技(一种最新被发现的生理调节器)为正在经历严重疾病的患者发现和临床开发药物。该公司专注于开发用于治疗面肩胛肱型肌营养不良症(FSHD)和肢节型肌营养不良症(LGMD)2B等罕见疾病的Physiocrine疗法。该公司正在开发Resolaris。Resolaris是一种用于治疗罕见免疫源性肌病(RMICs)的静脉注射蛋白治疗剂。该公司正在调查用于LGMD2B患者的Resolaris。该公司正在开展三项针对早发型FSHD患者及成年FSHD或LGMD2B患者的开放性试验,以及一项针成年FSHD患者的长期延伸研究。该公司没有产生任何收入。
展开

微牛提供aTyr Pharma Inc(NASDAQ-LIFE)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的LIFE股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易LIFE股票基本功能。